J, Stackowicz; CM, Gillis; O, Godon; B, Iannascoli; E, Conde; E, Leveque; WPM, Worrall; SJ, Galli; P, Bruhns; LL, Reber; F, Jönsson Conditional neutrophil depletion challenges their contribution to mouse models of anaphylaxis. Article de journal Dans: Allergy, 2023. @article{37022292,
title = {Conditional neutrophil depletion challenges their contribution to mouse models of anaphylaxis.},
author = {Stackowicz J and Gillis CM and Godon O and Iannascoli B and Conde E and Leveque E and Worrall WPM and Galli SJ and Bruhns P and Reber LL and Jönsson F},
url = {https://pubmed.ncbi.nlm.nih.gov/37022292/},
doi = {10.1111/all.15738},
year = {2023},
date = {2023-04-06},
journal = {Allergy},
keywords = {},
pubstate = {published},
tppubtype = {article}
}
|
Martin-Blondel, Guillaume; Marcelin, Anne-Geneviève; Soulié, Cathia; Kaisaridi, Sofia; Lusivika-Nzinga, Clovis; Zafilaza, Karen; Dorival, Céline; Nailler, Laura; Boston, Anaïs; Ronchetti, Anne-Marie; Melenotte, Cléa; Cabié, André; Choquet, Christophe; Trinh-Duc, Albert; Lacombe, Karine; Gaube, Géraldine; Coustillères, François; Pourcher, Valérie; Martellosio, Jean-Philippe; Peiffer-Smadja, Nathan; Chauveau, Marie; Housset, Pierre; Piroth, Lionel; Devaux, Mathilde; Pialoux, Gilles; Martin, Aurélie; Dubee, Vincent; Frey, Jérôme; Bot, Audrey Le; Cazanave, Charles; Petua, Philippe; Liblau, Roland; Carrat, Fabrice; Yordanov, Youri Time to negative PCR conversion amongst high-risk patients with mild-to-moderate Omicron BA.1 and BA.2 COVID-19 treated with sotrovimab or nirmatrelvir Article de journal Dans: Clin Microbiol Infect, vol. 29, no. 4, p. 543.e5–543.e9, 2023, ISSN: 1469-0691. @article{pmid36586513,
title = {Time to negative PCR conversion amongst high-risk patients with mild-to-moderate Omicron BA.1 and BA.2 COVID-19 treated with sotrovimab or nirmatrelvir},
author = {Guillaume Martin-Blondel and Anne-Geneviève Marcelin and Cathia Soulié and Sofia Kaisaridi and Clovis Lusivika-Nzinga and Karen Zafilaza and Céline Dorival and Laura Nailler and Anaïs Boston and Anne-Marie Ronchetti and Cléa Melenotte and André Cabié and Christophe Choquet and Albert Trinh-Duc and Karine Lacombe and Géraldine Gaube and François Coustillères and Valérie Pourcher and Jean-Philippe Martellosio and Nathan Peiffer-Smadja and Marie Chauveau and Pierre Housset and Lionel Piroth and Mathilde Devaux and Gilles Pialoux and Aurélie Martin and Vincent Dubee and Jérôme Frey and Audrey Le Bot and Charles Cazanave and Philippe Petua and Roland Liblau and Fabrice Carrat and Youri Yordanov},
doi = {10.1016/j.cmi.2022.12.016},
issn = {1469-0691},
year = {2023},
date = {2023-04-01},
urldate = {2023-04-01},
journal = {Clin Microbiol Infect},
volume = {29},
number = {4},
pages = {543.e5--543.e9},
abstract = {OBJECTIVES: Our aim was to compare the clinical and virological outcomes in Omicron BA.1- and BA.2-infected patients who received sotrovimab with those in patients who received nirmatrelvir for the prevention of severe COVID-19.nnMETHODS: In this multi-centric, prospective ANRS 0003S CoCoPrev cohort study, patients at a high risk of progression of mild-to-moderate BA.1 or BA.2 COVID-19 who received sotrovimab or nirmatrelvir were included. The proportion of patients with progression to severe COVID-19, time between the start of treatment to negative PCR conversion, SARS-CoV-2 viral decay, and characterization of resistance variants were determined. A multi-variable Cox proportional hazard model was used to determine the time to negative PCR conversion and a mixed-effect model for the dynamics of viral decay.nnRESULTS: Amongst 255 included patients, 199 (80%) received ≥3 vaccine doses, 195 (76%) received sotrovimab, and 60 (24%) received nirmatrelvir. On day 28, new COVID-19-related hospitalization occurred in 4 of 193 (2%; 95% CI, 1-5%) sotrovimab-treated patients and 0 of 55 nirmatrelvir-treated patients (p 0.24). One out of the 55 nirmatrelvir-treated patients died (2%; 95% CI, 0-10%). The median time to negative PCR conversion was 11.5 days (95% CI, 10.5-13) in the sotrovimab-treated patients vs. 4 days (95% CI, 4-9) in the nirmatrelvir-treated patients (p < 0.001). Viral decay was faster in the patients who received nirmatrelvir (p < 0.001). In the multi-variable analysis, nirmatrelvir and nasopharyngeal PCR cycle threshold values were independently associated with faster conversion to negative PCR (hazard ratio, 2.35; 95% CI, 1.56-3.56; p < 0.0001 and hazard ratio, 1.05; 95% CI, 1.01-1.08; p 0.01, respectively).nnCONCLUSIONS: Early administration of nirmatrelvir in high-risk patients compared with that of sotrovimab was associated with faster viral clearance. This may participate to decrease transmission and prevent viral resistance.},
keywords = {},
pubstate = {published},
tppubtype = {article}
}
OBJECTIVES: Our aim was to compare the clinical and virological outcomes in Omicron BA.1- and BA.2-infected patients who received sotrovimab with those in patients who received nirmatrelvir for the prevention of severe COVID-19.nnMETHODS: In this multi-centric, prospective ANRS 0003S CoCoPrev cohort study, patients at a high risk of progression of mild-to-moderate BA.1 or BA.2 COVID-19 who received sotrovimab or nirmatrelvir were included. The proportion of patients with progression to severe COVID-19, time between the start of treatment to negative PCR conversion, SARS-CoV-2 viral decay, and characterization of resistance variants were determined. A multi-variable Cox proportional hazard model was used to determine the time to negative PCR conversion and a mixed-effect model for the dynamics of viral decay.nnRESULTS: Amongst 255 included patients, 199 (80%) received ≥3 vaccine doses, 195 (76%) received sotrovimab, and 60 (24%) received nirmatrelvir. On day 28, new COVID-19-related hospitalization occurred in 4 of 193 (2%; 95% CI, 1-5%) sotrovimab-treated patients and 0 of 55 nirmatrelvir-treated patients (p 0.24). One out of the 55 nirmatrelvir-treated patients died (2%; 95% CI, 0-10%). The median time to negative PCR conversion was 11.5 days (95% CI, 10.5-13) in the sotrovimab-treated patients vs. 4 days (95% CI, 4-9) in the nirmatrelvir-treated patients (p < 0.001). Viral decay was faster in the patients who received nirmatrelvir (p < 0.001). In the multi-variable analysis, nirmatrelvir and nasopharyngeal PCR cycle threshold values were independently associated with faster conversion to negative PCR (hazard ratio, 2.35; 95% CI, 1.56-3.56; p < 0.0001 and hazard ratio, 1.05; 95% CI, 1.01-1.08; p 0.01, respectively).nnCONCLUSIONS: Early administration of nirmatrelvir in high-risk patients compared with that of sotrovimab was associated with faster viral clearance. This may participate to decrease transmission and prevent viral resistance. |
E, Lamanna; E, Conde; A, Mougel; J, Bonnefoy; F, Colaone; O, Godon; S, Hamdi; JBJ, Kamphuis; B, Drouet; V, Serra; P, Bruhns; LL, Reber A vaccine targeting human IL-4 and IL-13 protects against asthma in humanized mice. Article de journal Dans: Allergy, 2023. @article{36799426,
title = {A vaccine targeting human IL-4 and IL-13 protects against asthma in humanized mice.},
author = {Lamanna E and Conde E and Mougel A and Bonnefoy J and Colaone F and Godon O and Hamdi S and Kamphuis JBJ and Drouet B and Serra V and Bruhns P and Reber LL},
url = {https://pubmed.ncbi.nlm.nih.gov/36799426/},
doi = {10.1111/all.15680},
year = {2023},
date = {2023-02-17},
journal = {Allergy},
keywords = {},
pubstate = {published},
tppubtype = {article}
}
|
Faure, Fabrice; Yshii, Lidia; Renno, Toufic; Coste, Isabelle; Joubert, Bastien; Desestret, Virginie; Liblau, Roland; Honnorat, Jérôme A Pilot Study to Develop Paraneoplastic Cerebellar Degeneration Mouse Model Article de journal Dans: Cerebellum, 2023, ISSN: 1473-4230. @article{pmid36729270,
title = {A Pilot Study to Develop Paraneoplastic Cerebellar Degeneration Mouse Model},
author = {Fabrice Faure and Lidia Yshii and Toufic Renno and Isabelle Coste and Bastien Joubert and Virginie Desestret and Roland Liblau and Jérôme Honnorat},
doi = {10.1007/s12311-023-01524-6},
issn = {1473-4230},
year = {2023},
date = {2023-02-01},
urldate = {2023-02-01},
journal = {Cerebellum},
abstract = {Modeling paraneoplastic neurological diseases to understand the immune mechanisms leading to neuronal death is a major challenge given the rarity and terminal access of patients' autopsies. Here, we present a pilot study aiming at modeling paraneoplastic cerebellar degeneration with Yo autoantibodies (Yo-PCD). Female mice were implanted with an ovarian carcinoma cell line expressing CDR2 and CDR2L, the known antigens recognized by anti-Yo antibodies. To boost the immune response, we also immunized the mice by injecting antigens with diverse adjuvants and immune checkpoint inhibitors. Ataxia and gait instability were assessed in treated mice as well as autoantibody levels, Purkinje cell density, and immune infiltration in the cerebellum. We observed the production of anti-Yo antibodies in the CSF and serum of all immunized mice. Brain immunoreaction varied depending on the site of implantation of the tumor, with subcutaneous administration leading to a massive infiltration of immune cells in the meningeal spaces, choroid plexus, and cerebellar parenchyma. However, we did not observe massive Purkinje cell death nor any motor impairments in any of the experimental groups. Self-sustained neuro-inflammation might require a longer time to build up in our model. Unusual tumor antigen presentation and/or intrinsic, species-specific factors required for pro-inflammatory engagement in the brain may also constitute strong limitations to achieve massive recruitment of antigen-specific T-cells and killing of antigen-expressing neurons in this mouse model.},
keywords = {},
pubstate = {published},
tppubtype = {article}
}
Modeling paraneoplastic neurological diseases to understand the immune mechanisms leading to neuronal death is a major challenge given the rarity and terminal access of patients' autopsies. Here, we present a pilot study aiming at modeling paraneoplastic cerebellar degeneration with Yo autoantibodies (Yo-PCD). Female mice were implanted with an ovarian carcinoma cell line expressing CDR2 and CDR2L, the known antigens recognized by anti-Yo antibodies. To boost the immune response, we also immunized the mice by injecting antigens with diverse adjuvants and immune checkpoint inhibitors. Ataxia and gait instability were assessed in treated mice as well as autoantibody levels, Purkinje cell density, and immune infiltration in the cerebellum. We observed the production of anti-Yo antibodies in the CSF and serum of all immunized mice. Brain immunoreaction varied depending on the site of implantation of the tumor, with subcutaneous administration leading to a massive infiltration of immune cells in the meningeal spaces, choroid plexus, and cerebellar parenchyma. However, we did not observe massive Purkinje cell death nor any motor impairments in any of the experimental groups. Self-sustained neuro-inflammation might require a longer time to build up in our model. Unusual tumor antigen presentation and/or intrinsic, species-specific factors required for pro-inflammatory engagement in the brain may also constitute strong limitations to achieve massive recruitment of antigen-specific T-cells and killing of antigen-expressing neurons in this mouse model. |
Texier, Baptiste; Prime, Morgane; Atamena, Djamaa; Belenguer, Pascale; Szelechowski, Marion Mortalin/Hspa9 involvement and therapeutic perspective in Parkinson's disease Article de journal Dans: Neural Regen Res, vol. 18, no. 2, p. 293–298, 2023, ISSN: 1673-5374. @article{pmid35900406c,
title = {Mortalin/Hspa9 involvement and therapeutic perspective in Parkinson's disease},
author = {Baptiste Texier and Morgane Prime and Djamaa Atamena and Pascale Belenguer and Marion Szelechowski},
doi = {10.4103/1673-5374.346487},
issn = {1673-5374},
year = {2023},
date = {2023-02-01},
urldate = {2023-02-01},
journal = {Neural Regen Res},
volume = {18},
number = {2},
pages = {293--298},
abstract = {By controlling the proper folding of proteins imported into mitochondria and ensuring crosstalk between the reticulum and mitochondria to modulate intracellular calcium fluxes, Mortalin is a chaperone protein that plays crucial roles in neuronal homeostasis and activity. However, its expression and stability are strongly modified in response to cellular stresses, in particular upon altered oxidative conditions during neurodegeneration. Here, we report and discuss the abundant literature that has highlighted its contribution to the pathophysiology of Parkinson's disease, as well as its therapeutic and prognostic potential in this still incurable pathology.},
keywords = {},
pubstate = {published},
tppubtype = {article}
}
By controlling the proper folding of proteins imported into mitochondria and ensuring crosstalk between the reticulum and mitochondria to modulate intracellular calcium fluxes, Mortalin is a chaperone protein that plays crucial roles in neuronal homeostasis and activity. However, its expression and stability are strongly modified in response to cellular stresses, in particular upon altered oxidative conditions during neurodegeneration. Here, we report and discuss the abundant literature that has highlighted its contribution to the pathophysiology of Parkinson's disease, as well as its therapeutic and prognostic potential in this still incurable pathology. |
Texier, Baptiste; Prime, Morgane; Atamena, Djamaa; Belenguer, Pascale; Szelechowski, Marion Mortalin/Hspa9 involvement and therapeutic perspective in Parkinson's disease Article de journal Dans: Neural Regen Res, vol. 18, no. 2, p. 293–298, 2023, ISSN: 1673-5374. @article{pmid35900406b,
title = {Mortalin/Hspa9 involvement and therapeutic perspective in Parkinson's disease},
author = {Baptiste Texier and Morgane Prime and Djamaa Atamena and Pascale Belenguer and Marion Szelechowski},
doi = {10.4103/1673-5374.346487},
issn = {1673-5374},
year = {2023},
date = {2023-02-01},
journal = {Neural Regen Res},
volume = {18},
number = {2},
pages = {293--298},
abstract = {By controlling the proper folding of proteins imported into mitochondria and ensuring crosstalk between the reticulum and mitochondria to modulate intracellular calcium fluxes, Mortalin is a chaperone protein that plays crucial roles in neuronal homeostasis and activity. However, its expression and stability are strongly modified in response to cellular stresses, in particular upon altered oxidative conditions during neurodegeneration. Here, we report and discuss the abundant literature that has highlighted its contribution to the pathophysiology of Parkinson's disease, as well as its therapeutic and prognostic potential in this still incurable pathology.},
keywords = {},
pubstate = {published},
tppubtype = {article}
}
By controlling the proper folding of proteins imported into mitochondria and ensuring crosstalk between the reticulum and mitochondria to modulate intracellular calcium fluxes, Mortalin is a chaperone protein that plays crucial roles in neuronal homeostasis and activity. However, its expression and stability are strongly modified in response to cellular stresses, in particular upon altered oxidative conditions during neurodegeneration. Here, we report and discuss the abundant literature that has highlighted its contribution to the pathophysiology of Parkinson's disease, as well as its therapeutic and prognostic potential in this still incurable pathology. |
Texier, Baptiste; Prime, Morgane; Atamena, Djamaa; Belenguer, Pascale; Szelechowski, Marion Mortalin/Hspa9 involvement and therapeutic perspective in Parkinson's disease Article de journal Dans: Neural Regen Res, vol. 18, no. 2, p. 293–298, 2023, ISSN: 1673-5374. @article{pmid35900406,
title = {Mortalin/Hspa9 involvement and therapeutic perspective in Parkinson's disease},
author = {Baptiste Texier and Morgane Prime and Djamaa Atamena and Pascale Belenguer and Marion Szelechowski},
doi = {10.4103/1673-5374.346487},
issn = {1673-5374},
year = {2023},
date = {2023-02-01},
journal = {Neural Regen Res},
volume = {18},
number = {2},
pages = {293--298},
abstract = {By controlling the proper folding of proteins imported into mitochondria and ensuring crosstalk between the reticulum and mitochondria to modulate intracellular calcium fluxes, Mortalin is a chaperone protein that plays crucial roles in neuronal homeostasis and activity. However, its expression and stability are strongly modified in response to cellular stresses, in particular upon altered oxidative conditions during neurodegeneration. Here, we report and discuss the abundant literature that has highlighted its contribution to the pathophysiology of Parkinson's disease, as well as its therapeutic and prognostic potential in this still incurable pathology.},
keywords = {},
pubstate = {published},
tppubtype = {article}
}
By controlling the proper folding of proteins imported into mitochondria and ensuring crosstalk between the reticulum and mitochondria to modulate intracellular calcium fluxes, Mortalin is a chaperone protein that plays crucial roles in neuronal homeostasis and activity. However, its expression and stability are strongly modified in response to cellular stresses, in particular upon altered oxidative conditions during neurodegeneration. Here, we report and discuss the abundant literature that has highlighted its contribution to the pathophysiology of Parkinson's disease, as well as its therapeutic and prognostic potential in this still incurable pathology. |
Fourgeaud, Jacques; Magny, Jean-François; Couderc, Sophie; Garcia, Patricia; Maillotte, Anne-Marie; Benard, Melinda; Pinquier, Didier; Minodier, Philippe; Astruc, Dominique; Patural, Hugues; Ugolin, Melissa; Parat, Sophie; Guillois, Bernard; Garenne, Armelle; Guilleminot, Tiffany; Parodi, Marine; Bussières, Laurence; Ville, Yves; Leruez-Ville, Marianne Clinical Value of Serial Quantitative Analysis of Cytomegalovirus DNA in Blood and Saliva Over the First 24 Months of Life in Congenital Infection: The French Cymepedia Cohort Article de journal Dans: The Journal of Pediatrics, vol. 253, p. 197–204.e5, 2023, ISSN: 0022-3476. @article{Fourgeaud2023,
title = {Clinical Value of Serial Quantitative Analysis of Cytomegalovirus DNA in Blood and Saliva Over the First 24 Months of Life in Congenital Infection: The French Cymepedia Cohort},
author = {Jacques Fourgeaud and Jean-François Magny and Sophie Couderc and Patricia Garcia and Anne-Marie Maillotte and Melinda Benard and Didier Pinquier and Philippe Minodier and Dominique Astruc and Hugues Patural and Melissa Ugolin and Sophie Parat and Bernard Guillois and Armelle Garenne and Tiffany Guilleminot and Marine Parodi and Laurence Bussières and Yves Ville and Marianne Leruez-Ville},
doi = {10.1016/j.jpeds.2022.09.040},
issn = {0022-3476},
year = {2023},
date = {2023-02-00},
urldate = {2023-02-00},
journal = {The Journal of Pediatrics},
volume = {253},
pages = {197--204.e5},
publisher = {Elsevier BV},
keywords = {},
pubstate = {published},
tppubtype = {article}
}
|
Starkl, Philipp; Jonsson, Gustav; Artner, Tyler; Turnes, Bruna Lenfers; Serhan, Nadine; Oliveira, Tiago; Gail, Laura-Marie; Stejskal, Karel; Channon, Keith M.; Köcher, Thomas; Stary, Georg; Klang, Victoria; Gaudenzio, Nicolas; Knapp, Sylvia; Woolf, Clifford J.; Penninger, Josef M.; Cronin, Shane J. F. Pre-print | Mast cell-derived BH4 is a critical mediator of postoperative pain Article de journal Dans: bioRxiv, 2023. @article{Starkl2023,
title = {Pre-print | Mast cell-derived BH4 is a critical mediator of postoperative pain},
author = {Philipp Starkl and Gustav Jonsson and Tyler Artner and Bruna Lenfers Turnes and Nadine Serhan and Tiago Oliveira and Laura-Marie Gail and Karel Stejskal and Keith M. Channon and Thomas Köcher and Georg Stary and Victoria Klang and Nicolas Gaudenzio and Sylvia Knapp and Clifford J. Woolf and Josef M. Penninger and Shane J.F. Cronin},
url = {https://www.biorxiv.org/content/10.1101/2023.01.24.525378v1},
year = {2023},
date = {2023-01-24},
journal = {bioRxiv},
keywords = {},
pubstate = {published},
tppubtype = {article}
}
|
de Sèze, Jérôme; Maillart, Elisabeth; Gueguen, Antoine; Laplaud, David A; Michel, Laure; Thouvenot, Eric; Zephir, Hélène; Zimmer, Luc; Biotti, Damien; Liblau, Roland Anti-CD20 therapies in multiple sclerosis: From pathology to the clinic Article de journal Dans: Front Immunol, vol. 14, p. 1004795, 2023, ISSN: 1664-3224. @article{pmid37033984,
title = {Anti-CD20 therapies in multiple sclerosis: From pathology to the clinic},
author = {Jérôme de Sèze and Elisabeth Maillart and Antoine Gueguen and David A Laplaud and Laure Michel and Eric Thouvenot and Hélène Zephir and Luc Zimmer and Damien Biotti and Roland Liblau},
doi = {10.3389/fimmu.2023.1004795},
issn = {1664-3224},
year = {2023},
date = {2023-01-01},
urldate = {2023-01-01},
journal = {Front Immunol},
volume = {14},
pages = {1004795},
abstract = {The immune system plays a significant role in multiple sclerosis. While MS was historically thought to be T cell-mediated, multiple pieces of evidence now support the view that B cells are essential players in multiple sclerosis pathogenic processes. High-efficacy disease-modifying therapies that target the immune system have emerged over the past two decades. Anti-CD20 monoclonal antibodies selectively deplete CD20+ B and CD20+ T cells and efficiently suppress inflammatory disease activity. These monotherapies prevent relapses, reduce new or active magnetic resonance imaging brain lesions, and lessen disability progression in patients with relapsing multiple sclerosis. Rituximab, ocrelizumab, and ofatumumab are currently used in clinical practice, while phase III clinical trials for ublituximab have been recently completed. In this review, we compare the four anti-CD20 antibodies in terms of their mechanisms of action, routes of administration, immunological targets, and pharmacokinetic properties. A deeper understanding of the individual properties of these molecules in relation to their efficacy and safety profiles is critical for their use in clinical practice.},
keywords = {},
pubstate = {published},
tppubtype = {article}
}
The immune system plays a significant role in multiple sclerosis. While MS was historically thought to be T cell-mediated, multiple pieces of evidence now support the view that B cells are essential players in multiple sclerosis pathogenic processes. High-efficacy disease-modifying therapies that target the immune system have emerged over the past two decades. Anti-CD20 monoclonal antibodies selectively deplete CD20+ B and CD20+ T cells and efficiently suppress inflammatory disease activity. These monotherapies prevent relapses, reduce new or active magnetic resonance imaging brain lesions, and lessen disability progression in patients with relapsing multiple sclerosis. Rituximab, ocrelizumab, and ofatumumab are currently used in clinical practice, while phase III clinical trials for ublituximab have been recently completed. In this review, we compare the four anti-CD20 antibodies in terms of their mechanisms of action, routes of administration, immunological targets, and pharmacokinetic properties. A deeper understanding of the individual properties of these molecules in relation to their efficacy and safety profiles is critical for their use in clinical practice. |
Ayoub, Ikram; Dauvilliers, Yves; Barateau, Lucie; Vermeulen, Thaïs; Mouton-Barbosa, Emmanuelle; Marcellin, Marlène; Gonzalez-de-Peredo, Anne; Gross, Catharina C; Saoudi, Abdelhadi; Liblau, Roland Cerebrospinal fluid proteomics in recent-onset Narcolepsy type 1 reveals activation of the complement system Article de journal Dans: Front Immunol, vol. 14, p. 1108682, 2023, ISSN: 1664-3224. @article{pmid37122721,
title = {Cerebrospinal fluid proteomics in recent-onset Narcolepsy type 1 reveals activation of the complement system},
author = {Ikram Ayoub and Yves Dauvilliers and Lucie Barateau and Thaïs Vermeulen and Emmanuelle Mouton-Barbosa and Marlène Marcellin and Anne Gonzalez-de-Peredo and Catharina C Gross and Abdelhadi Saoudi and Roland Liblau},
doi = {10.3389/fimmu.2023.1108682},
issn = {1664-3224},
year = {2023},
date = {2023-01-01},
urldate = {2023-01-01},
journal = {Front Immunol},
volume = {14},
pages = {1108682},
abstract = {INTRODUCTION: Narcolepsy type 1 (NT1) is a rare, chronic and disabling neurological disease causing excessive daytime sleepiness and cataplexy. NT1 is characterized pathologically by an almost complete loss of neurons producing the orexin neuropeptides in the lateral hypothalamus. Genetic and environmental factors strongly suggest the involvement of the immune system in the loss of orexin neurons. The cerebrospinal fluid (CSF), secreted locally and surrounding the central nervous system (CNS), represents an accessible window into CNS pathological processes.nnMETHODS: To gain insight into the biological and molecular changes in NT1 patients, we performed a comparative proteomics analysis of the CSF from 21 recent-onset NT1 patients and from two control groups: group 1 with somatoform disorders, and group 2 patients with hypersomnia other than NT1, to control for any potential effect of sleep disturbances on CSF composition. To achieve an optimal proteomic coverage analysis, the twelve most abundant CSF proteins were depleted, and samples were analyzed by nano-flow liquid chromatography tandem mass spectrometry (nano-LC-MS/MS) using the latest generation of hybrid Orbitrap mass spectrometer.nnRESULTS AND DISCUSSION: Our study allowed the identification and quantification of up to 1943 proteins, providing a remarkably deep analysis of the CSF proteome. Interestingly, gene set enrichment analysis indicated that the complement and coagulation systems were enriched and significantly activated in NT1 patients in both cohorts analyzed. Notably, the lectin and alternative complement pathway as well as the downstream lytic membrane attack complex were congruently increased in NT1. Our data suggest that the complement dysregulation in NT1 patients can contribute to immunopathology either by directly promoting tissue damage or as part of local inflammatory responses. We therefore reveal an altered composition of the CSF proteome in NT1 patients, which points to an ongoing inflammatory process contributed, at least in part, by the complement system.},
keywords = {},
pubstate = {published},
tppubtype = {article}
}
INTRODUCTION: Narcolepsy type 1 (NT1) is a rare, chronic and disabling neurological disease causing excessive daytime sleepiness and cataplexy. NT1 is characterized pathologically by an almost complete loss of neurons producing the orexin neuropeptides in the lateral hypothalamus. Genetic and environmental factors strongly suggest the involvement of the immune system in the loss of orexin neurons. The cerebrospinal fluid (CSF), secreted locally and surrounding the central nervous system (CNS), represents an accessible window into CNS pathological processes.nnMETHODS: To gain insight into the biological and molecular changes in NT1 patients, we performed a comparative proteomics analysis of the CSF from 21 recent-onset NT1 patients and from two control groups: group 1 with somatoform disorders, and group 2 patients with hypersomnia other than NT1, to control for any potential effect of sleep disturbances on CSF composition. To achieve an optimal proteomic coverage analysis, the twelve most abundant CSF proteins were depleted, and samples were analyzed by nano-flow liquid chromatography tandem mass spectrometry (nano-LC-MS/MS) using the latest generation of hybrid Orbitrap mass spectrometer.nnRESULTS AND DISCUSSION: Our study allowed the identification and quantification of up to 1943 proteins, providing a remarkably deep analysis of the CSF proteome. Interestingly, gene set enrichment analysis indicated that the complement and coagulation systems were enriched and significantly activated in NT1 patients in both cohorts analyzed. Notably, the lectin and alternative complement pathway as well as the downstream lytic membrane attack complex were congruently increased in NT1. Our data suggest that the complement dysregulation in NT1 patients can contribute to immunopathology either by directly promoting tissue damage or as part of local inflammatory responses. We therefore reveal an altered composition of the CSF proteome in NT1 patients, which points to an ongoing inflammatory process contributed, at least in part, by the complement system. |
Astier, Anne L; Kofler, David M Editorial: Dysregulation of Th17 and Treg cells in autoimmune diseases Article de journal Dans: Front Immunol, vol. 14, p. 1151836, 2023, ISSN: 1664-3224. @article{pmid36865563,
title = {Editorial: Dysregulation of Th17 and Treg cells in autoimmune diseases},
author = {Anne L Astier and David M Kofler},
doi = {10.3389/fimmu.2023.1151836},
issn = {1664-3224},
year = {2023},
date = {2023-01-01},
urldate = {2023-01-01},
journal = {Front Immunol},
volume = {14},
pages = {1151836},
keywords = {},
pubstate = {published},
tppubtype = {article}
}
|
Lacouture, Claire; Prunier, Guilhèn; Dupré, Loïc Kinetic measurements of human CD8+ Ŧ cell cytotoxic activity in a 384-well plate format Article de journal Dans: Methods Cell Biol, vol. 178, p. 121–133, 2023, ISSN: 0091-679X. @article{lacouture_kinetic_2023,
title = {Kinetic measurements of human CD8+ Ŧ cell cytotoxic activity in a 384-well plate format},
author = {Lacouture, Claire and Prunier, Guilhèn and Dupré, Loïc},
doi = {10.1016/bs.mcb.2022.07.014},
issn = {0091-679X},
year = {2023},
date = {2023-01-01},
journal = {Methods Cell Biol},
volume = {178},
pages = {121--133},
abstract = {The elimination of infected or cancerous cells by CD8+ cytotoxic T lymphocytes (CTL) is a crucial effector mechanism of the immune system. Upon antigen recognition, CTL stop migrating, establish a tight contact with target cells and deliver cytotoxic molecules such as perforin and granzymes that lead to target cell apoptosis. The ability of CTL to control a population of infected cells or a tumor depends on multiple parameters, such as the relative numbers of CTL and target cells, the intrinsic cytotoxic activity of CTL, the intrinsic resistance of target cells and the repertoire of immune checkpoints tuning cytotoxic activity at the CTL:target cell interface. In this context, in vitro assays to precisely measure CTL:target cell interactions and cytotoxic activity over time are required to monitor natural or therapeutic responses. We here present an image-based method that allows recording of positions and survival of CTL and target cells over time in a high-throughput format. The protocol relies on the staining of CTL and target cells with fluorescent dyes and the automated imaging of cells deposited in wells of a 384-well plate with an automated cell imaging device. We discuss potential applications offered by the kinetic assessment of CTL cytotoxic activity in a high-throughput format.},
keywords = {},
pubstate = {published},
tppubtype = {article}
}
The elimination of infected or cancerous cells by CD8+ cytotoxic T lymphocytes (CTL) is a crucial effector mechanism of the immune system. Upon antigen recognition, CTL stop migrating, establish a tight contact with target cells and deliver cytotoxic molecules such as perforin and granzymes that lead to target cell apoptosis. The ability of CTL to control a population of infected cells or a tumor depends on multiple parameters, such as the relative numbers of CTL and target cells, the intrinsic cytotoxic activity of CTL, the intrinsic resistance of target cells and the repertoire of immune checkpoints tuning cytotoxic activity at the CTL:target cell interface. In this context, in vitro assays to precisely measure CTL:target cell interactions and cytotoxic activity over time are required to monitor natural or therapeutic responses. We here present an image-based method that allows recording of positions and survival of CTL and target cells over time in a high-throughput format. The protocol relies on the staining of CTL and target cells with fluorescent dyes and the automated imaging of cells deposited in wells of a 384-well plate with an automated cell imaging device. We discuss potential applications offered by the kinetic assessment of CTL cytotoxic activity in a high-throughput format. |
Prunier, Guilhèn; Chaves, Beatriz; Lacouture, Claire; Dupré, Loïc Metrics of 2D immunological synapses in human Ŧ cells via high-content confocal cell imaging Article de journal Dans: Methods Cell Biol, vol. 178, p. 107–120, 2023, ISSN: 0091-679X. @article{prunier_metrics_2023,
title = {Metrics of 2D immunological synapses in human Ŧ cells via high-content confocal cell imaging},
author = {Prunier, Guilhèn and Chaves, Beatriz and Lacouture, Claire and Dupré, Loïc},
doi = {10.1016/bs.mcb.2022.07.013},
issn = {0091-679X},
year = {2023},
date = {2023-01-01},
journal = {Methods Cell Biol},
volume = {178},
pages = {107--120},
abstract = {Immunological synapses (IS) are the privileged site of complex information transfer between T cells and antigen presenting cells. IS are highly structured in terms of actin and tubulin cytoskeleton organization, receptor and proximal signal patterning, and intracellular organelle polarization. The magnitude and quality of T cell responses upon antigen recognition is dependent on IS molecular organization. For that reason, methods to precisely assess IS parameters are crucial to monitor T cell activation and function in health and disease, but also for T cell centered therapeutic intervention. Confocal and super-resolution microscopy approaches have allowed to characterize the complex structure of the T cell IS. However, those approaches suffer from a low-throughput and low-content format precluding multi-parametric classification of IS across large numbers of samples or stimulatory conditions. Here, we present a protocol of high-content confocal cell imaging in a 384-well plate format adapted to the unbiased analysis of primary T cells forming IS over pre-coated stimulatory molecules. The protocol focuses on the staining of F-actin, pericentrin and granzyme B in CD8+ T cells, but is transposable to other IS molecular markers and lymphocyte subsets. We discuss potential applications offered by the multi-parametric characterization of T cell IS in a high-throughput format.},
keywords = {},
pubstate = {published},
tppubtype = {article}
}
Immunological synapses (IS) are the privileged site of complex information transfer between T cells and antigen presenting cells. IS are highly structured in terms of actin and tubulin cytoskeleton organization, receptor and proximal signal patterning, and intracellular organelle polarization. The magnitude and quality of T cell responses upon antigen recognition is dependent on IS molecular organization. For that reason, methods to precisely assess IS parameters are crucial to monitor T cell activation and function in health and disease, but also for T cell centered therapeutic intervention. Confocal and super-resolution microscopy approaches have allowed to characterize the complex structure of the T cell IS. However, those approaches suffer from a low-throughput and low-content format precluding multi-parametric classification of IS across large numbers of samples or stimulatory conditions. Here, we present a protocol of high-content confocal cell imaging in a 384-well plate format adapted to the unbiased analysis of primary T cells forming IS over pre-coated stimulatory molecules. The protocol focuses on the staining of F-actin, pericentrin and granzyme B in CD8+ T cells, but is transposable to other IS molecular markers and lymphocyte subsets. We discuss potential applications offered by the multi-parametric characterization of T cell IS in a high-throughput format. |
Guemas, E.; Coppee, R.; Menard, S.; du Manoir, M.; Nsango, S.; Makaba Mvumbi, D.; Nakoune, E.; Eboumbou Moukoko, C. E.; Bouyou Akotet, M. K.; Mirabeau, T. Y.; Manguin, S.; Malekita Yobi, D.; Akiana, J.; Kouna, L. C.; Mawili Mboumba, D. P.; Voumbo-Matoumona, D. F.; Otam, A. L.; Rubbo, P. A.; Lombart, J. P.; Kwanai, E.; Cohen, O.; Iriart, X.; Ayong, L.; Lekana-Douki, J. B.; Ariey, F.; Berry, A. Evolution and spread of Plasmodium falciparum mutations associated with resistance to sulfadoxine-pyrimethamine in central Africa: a cross-sectional study Article de journal Dans: Lancet Microbe, 2023, (doi: 10.1016/S2666-5247(23)00211-2.). @article{c,
title = {Evolution and spread of Plasmodium falciparum mutations associated with resistance to sulfadoxine-pyrimethamine in central Africa: a cross-sectional study},
author = {Guemas, E. and Coppee, R. and Menard, S. and du Manoir, M. and Nsango, S. and Makaba Mvumbi, D. and Nakoune, E. and Eboumbou Moukoko, C. E. and Bouyou Akotet, M. K. and Mirabeau, T. Y. and Manguin, S. and Malekita Yobi, D. and Akiana, J. and Kouna, L. C. and Mawili Mboumba, D. P. and Voumbo-Matoumona, D. F. and Otam, A. L. and Rubbo, P. A. and Lombart, J. P. and Kwanai, E. and Cohen, O. and Iriart, X. and Ayong, L. and Lekana-Douki, J. B. and Ariey, F. and Berry, A.},
year = {2023},
date = {2023-01-01},
journal = {Lancet Microbe},
abstract = {BACKGROUND: Efficacy of sulfadoxine-pyrimethamine, the malaria chemoprophylaxis used in pregnant women, and in children when combined with amodiaquine, is threatened by the accumulation of mutations in the Plasmodium falciparum dihydropteroate synthase (pfdhps) and dihydrofolate reductase (pfdhfr) genes. Data on the prevalence of resistant alleles in central Africa and the new pfdhps I431V mutation, particularly associated with other mutations to form the pfdhps vagKgs allele, are scarce. We explored the frequency and geographical distribution of pfdhps and pfdhfr mutations in central Africa in 2014-18, and assessed the evolutionary origin of the vagKgs allele. METHODS: Samples were collected at 18 health-care centres in seven countries (Angola, Cameroon, Central African Republic, Democratic Republic of the Congo, Gabon, Nigeria, and Republic of the Congo) from patients who showed possible symptoms of malaria between March 1, 2014, and Oct 31, 2018. Samples that were positive for P falciparum were transported to a laboratory in Toulouse, France, and genotyped. The frequency of pfdhfr and pfdhps mutations was studied in 1749 samples. Microsatellites in pfdhps flanking regions and whole-genome analysis compared with parasite genomes from the data-sharing network MalariaGEN were performed on samples carrying the vagKgs allele. FINDINGS: Mapping of the prevalence of single nucleotide polymorphisms and corresponding alleles of pfdhfr and pfdhps showed a substantial spread of alleles associated with sulfadoxine-pyrimethamine resistance in central Africa during the 2014-18 period, especially an increase going west to east in pfdhps alleles carrying the K540E and A581G mutations. A high prevalence of the pfdhps I431V mutation was observed in Cameroon (exceeding 50% in the northern region) and Nigeria. Genomic analysis showed a recent African emergence and a clonal expansion of the most frequent pfdhps vagKgs allele. INTERPRETATION: Reduced sulfadoxine-pyrimethamine efficacy due to increased resistance is a worrying situation, especially because the malaria transmission level is high in central Africa. Although the resistance phenotype remains to be confirmed, the emergence and spread of the vagKgs allele in west and central Africa could challenge the use of sulfadoxine-pyrimethamine. FUNDING: Toulouse Institute for Infectious and Inflammatory Diseases.},
note = {doi: 10.1016/S2666-5247(23)00211-2.},
keywords = {},
pubstate = {published},
tppubtype = {article}
}
BACKGROUND: Efficacy of sulfadoxine-pyrimethamine, the malaria chemoprophylaxis used in pregnant women, and in children when combined with amodiaquine, is threatened by the accumulation of mutations in the Plasmodium falciparum dihydropteroate synthase (pfdhps) and dihydrofolate reductase (pfdhfr) genes. Data on the prevalence of resistant alleles in central Africa and the new pfdhps I431V mutation, particularly associated with other mutations to form the pfdhps vagKgs allele, are scarce. We explored the frequency and geographical distribution of pfdhps and pfdhfr mutations in central Africa in 2014-18, and assessed the evolutionary origin of the vagKgs allele. METHODS: Samples were collected at 18 health-care centres in seven countries (Angola, Cameroon, Central African Republic, Democratic Republic of the Congo, Gabon, Nigeria, and Republic of the Congo) from patients who showed possible symptoms of malaria between March 1, 2014, and Oct 31, 2018. Samples that were positive for P falciparum were transported to a laboratory in Toulouse, France, and genotyped. The frequency of pfdhfr and pfdhps mutations was studied in 1749 samples. Microsatellites in pfdhps flanking regions and whole-genome analysis compared with parasite genomes from the data-sharing network MalariaGEN were performed on samples carrying the vagKgs allele. FINDINGS: Mapping of the prevalence of single nucleotide polymorphisms and corresponding alleles of pfdhfr and pfdhps showed a substantial spread of alleles associated with sulfadoxine-pyrimethamine resistance in central Africa during the 2014-18 period, especially an increase going west to east in pfdhps alleles carrying the K540E and A581G mutations. A high prevalence of the pfdhps I431V mutation was observed in Cameroon (exceeding 50% in the northern region) and Nigeria. Genomic analysis showed a recent African emergence and a clonal expansion of the most frequent pfdhps vagKgs allele. INTERPRETATION: Reduced sulfadoxine-pyrimethamine efficacy due to increased resistance is a worrying situation, especially because the malaria transmission level is high in central Africa. Although the resistance phenotype remains to be confirmed, the emergence and spread of the vagKgs allele in west and central Africa could challenge the use of sulfadoxine-pyrimethamine. FUNDING: Toulouse Institute for Infectious and Inflammatory Diseases. |
Cohen, O.; Guemas, E.; Menard, S.; Tsague Kenfack, M.; Talom Ngassa, C.; Iriart, X.; Bidzogo Lebobo, M.; Ondobo Ekae, C.; Eboumbou, C.; Tiyou Kenmeni, C.; Berry, A. Effect of sulfadoxine-pyrimethamine chemoprophylaxis in pregnant women on selection of the new P. falciparum dhps quintuple mutant carrying the I431V mutation Article de journal Dans: J Antimicrob Chemother, vol. 78, no. 3, p. 665-668, 2023, ( doi: 10.1093/jac/dkac432.). @article{c,
title = {Effect of sulfadoxine-pyrimethamine chemoprophylaxis in pregnant women on selection of the new P. falciparum dhps quintuple mutant carrying the I431V mutation},
author = {Cohen, O. and Guemas, E. and Menard, S. and Tsague Kenfack, M. and Talom Ngassa, C. and Iriart, X. and Bidzogo Lebobo, M. and Ondobo Ekae, C. and Eboumbou, C. and Tiyou Kenmeni, C. and Berry, A.},
year = {2023},
date = {2023-01-01},
journal = {J Antimicrob Chemother},
volume = {78},
number = {3},
pages = {665-668},
abstract = {BACKGROUND: A new mutation in the Plasmodium falciparum dihydropteroate synthetase gene (pfdhps), I431V, has been identified in several countries of Central and West Africa. This mutation is mostly found in association with four other SNPs on pfdhps (S436A, A437G, A581G and A613S), forming a quintuple mutant (vagKgs) and almost always associated with the Plasmodium falciparum dihydrofolate reductase gene (pfdhfr) CirnI (C50R, N51I, S108N) triple mutant. To date, nothing is known about the impact of this new pfdhps genotype on sulfadoxine-pyrimethamine (SP) resistance. OBJECTIVES: We sought to assess the prevalence of this pfdhps vagKgs quintuple mutant in two groups of pregnant women with malaria, one that took intermittent preventive treatment with sulfadoxine-pyrimethamine (IPTp-SP) and one that did not. METHODS: The pfdhfr and pfdhps genes from Plasmodium falciparum isolates collected in Yaounde (Cameroon) from pregnant women with symptomatic malaria under IPTp-SP or not, were sequenced. RESULTS: Of 159 patients evaluated, 70 had already taken SP during pregnancy and 89 had never taken SP. Only the vagKgs allele was significantly overrepresented in the SP+ group (21.4% versus 3.4%; P < 0.001), whereas the ISgKAA mutant, widely distributed in this area and known to be less susceptible to SP, tended to be less abundant in this group (48.6% versus 64.0%; P = 0.0503). CONCLUSIONS: We found a strong overrepresentation of the CirnI/vagKgs haplotype in the IPTp-SP pregnant group, suggesting a high level of resistance of this mutant to SP. This could compromise not only the effectiveness of IPTp-SP but also the seasonal malaria chemoprevention of young children, now widely implemented.},
note = { doi: 10.1093/jac/dkac432.},
keywords = {},
pubstate = {published},
tppubtype = {article}
}
BACKGROUND: A new mutation in the Plasmodium falciparum dihydropteroate synthetase gene (pfdhps), I431V, has been identified in several countries of Central and West Africa. This mutation is mostly found in association with four other SNPs on pfdhps (S436A, A437G, A581G and A613S), forming a quintuple mutant (vagKgs) and almost always associated with the Plasmodium falciparum dihydrofolate reductase gene (pfdhfr) CirnI (C50R, N51I, S108N) triple mutant. To date, nothing is known about the impact of this new pfdhps genotype on sulfadoxine-pyrimethamine (SP) resistance. OBJECTIVES: We sought to assess the prevalence of this pfdhps vagKgs quintuple mutant in two groups of pregnant women with malaria, one that took intermittent preventive treatment with sulfadoxine-pyrimethamine (IPTp-SP) and one that did not. METHODS: The pfdhfr and pfdhps genes from Plasmodium falciparum isolates collected in Yaounde (Cameroon) from pregnant women with symptomatic malaria under IPTp-SP or not, were sequenced. RESULTS: Of 159 patients evaluated, 70 had already taken SP during pregnancy and 89 had never taken SP. Only the vagKgs allele was significantly overrepresented in the SP+ group (21.4% versus 3.4%; P < 0.001), whereas the ISgKAA mutant, widely distributed in this area and known to be less susceptible to SP, tended to be less abundant in this group (48.6% versus 64.0%; P = 0.0503). CONCLUSIONS: We found a strong overrepresentation of the CirnI/vagKgs haplotype in the IPTp-SP pregnant group, suggesting a high level of resistance of this mutant to SP. This could compromise not only the effectiveness of IPTp-SP but also the seasonal malaria chemoprevention of young children, now widely implemented. |
Peron, J. M.; Larrue, H.; Izopet, J.; Buti, M. The pressing need for a global HEV vaccine Article de journal Dans: J Hepatol, vol. 79, no. 3, p. 876-880, 2023, ISSN: 1600-0641 (Electronic)
0168-8278 (Linking). @article{RN4495,
title = {The pressing need for a global HEV vaccine},
author = {Peron, J. M. and Larrue, H. and Izopet, J. and Buti, M.},
url = {https://www.ncbi.nlm.nih.gov/pubmed/37003442},
doi = {10.1016/j.jhep.2023.03.024},
issn = {1600-0641 (Electronic)
0168-8278 (Linking)},
year = {2023},
date = {2023-01-01},
journal = {J Hepatol},
volume = {79},
number = {3},
pages = {876-880},
keywords = {},
pubstate = {published},
tppubtype = {article}
}
|
Youness, A.; Cenac, C.; Faz-Lopez, B.; Grunenwald, S.; Barrat, F. J.; Chaumeil, J.; Mejia, J. E.; Guery, J. C. TLR8 escapes X chromosome inactivation in human monocytes and CD4(+) T cells Article de journal Dans: Biol Sex Differ, vol. 14, no. 1, p. 60, 2023, ISSN: 2042-6410 (Electronic)
2042-6410 (Linking). @article{RN2418,
title = {TLR8 escapes X chromosome inactivation in human monocytes and CD4(+) T cells},
author = {Youness, A. and Cenac, C. and Faz-Lopez, B. and Grunenwald, S. and Barrat, F. J. and Chaumeil, J. and Mejia, J. E. and Guery, J. C.},
url = {https://www.ncbi.nlm.nih.gov/pubmed/37723501},
doi = {10.1186/s13293-023-00544-5},
issn = {2042-6410 (Electronic)
2042-6410 (Linking)},
year = {2023},
date = {2023-01-01},
journal = {Biol Sex Differ},
volume = {14},
number = {1},
pages = {60},
keywords = {},
pubstate = {published},
tppubtype = {article}
}
|
Renaudineau, Y.; Muller, S.; Hedrich, C. M.; Chauveau, D.; Belliere, J.; De Almeida, S.; Damoiseaux, J.; Scherlinger, M.; Guery, J. C.; Sailler, L.; Bost, C. Immunological and translational key challenges in systemic lupus erythematosus: A symposium update Article de journal Dans: J Transl Autoimmun, vol. 6, p. 100199, 2023, ISSN: 2589-9090 (Electronic)
2589-9090 (Linking). @article{RN2417,
title = {Immunological and translational key challenges in systemic lupus erythematosus: A symposium update},
author = {Renaudineau, Y. and Muller, S. and Hedrich, C. M. and Chauveau, D. and Belliere, J. and De Almeida, S. and Damoiseaux, J. and Scherlinger, M. and Guery, J. C. and Sailler, L. and Bost, C.},
url = {https://www.ncbi.nlm.nih.gov/pubmed/37065621},
doi = {10.1016/j.jtauto.2023.100199},
issn = {2589-9090 (Electronic)
2589-9090 (Linking)},
year = {2023},
date = {2023-01-01},
journal = {J Transl Autoimmun},
volume = {6},
pages = {100199},
keywords = {},
pubstate = {published},
tppubtype = {article}
}
|
Miquel, C. H.; Faz-Lopez, B.; Guery, J. C. Influence of X chromosome in sex-biased autoimmune diseases Article de journal Dans: J Autoimmun, vol. 137, p. 102992, 2023, ISSN: 1095-9157 (Electronic)
0896-8411 (Linking). @article{RN2416,
title = {Influence of X chromosome in sex-biased autoimmune diseases},
author = {Miquel, C. H. and Faz-Lopez, B. and Guery, J. C.},
url = {https://www.ncbi.nlm.nih.gov/pubmed/36641351},
doi = {10.1016/j.jaut.2023.102992},
issn = {1095-9157 (Electronic)
0896-8411 (Linking)},
year = {2023},
date = {2023-01-01},
journal = {J Autoimmun},
volume = {137},
pages = {102992},
keywords = {},
pubstate = {published},
tppubtype = {article}
}
|